Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, affecting about 25% of the general population and up to 70–90% of obese or diabetic patients. Due to the increasing frequency of cardiometabolic polymorbidity phenotype and the fact that, on the one hand, NAFLD patients often have concomitant cardiovascular pathology and, on the other hand, that patients with cardiovascular disease (CVD) are often diagnosed with concomitant NAFLD, the relationship of NAFLD with CVD is currently subject to active study. Common metabolic risk factors and pathogenetic mechanisms such as systemic inflammation, endothelial dysfunction, lipid and glucose metabolism disorders, and insulin resistance are considered as the main determinants of the relationship between NAFLD and CVD. The involvement of the latter in the development of these diseases suggests that NAFLD and CVD are comorbid conditions, aggravating the course of each other, and, accordingly, the adjustment of lifestyle, risk factors and treatment of NAFLD can reduce the risks of CVD. In this regard, the purpose of this review is to analyze the relationship between NAFLD and CVD, as well as to discuss therapeutic strategies, in particular, the prospects of ursodeoxycholic acid in patients with NAFLD and CVD.

Keywords: comorbidity, hepatoprotectors, ursodeoxycholic acid, nonalcoholic fatty liver disease, cardiovascular disease